Last ¥12,250 JPY
Change Today +130.00 / 1.07%
Volume 145.9K
4528 On Other Exchanges
As of 11:08 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

ono pharmaceutical co ltd (4528) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/15 - ¥12,800
52 Week Low
05/21/14 - ¥7,710
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONO PHARMACEUTICAL CO LTD (4528)

Related News

No related news articles were found.

ono pharmaceutical co ltd (4528) Related Businessweek News

No Related Businessweek News Found

ono pharmaceutical co ltd (4528) Details

Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents in Japan and internationally. Its products primarily include Rivastach Patch to treat Alzheimer's disease; Glactiv and FORXIGA tablets for the treatment of type II diabetes; Emend capsules/Proemend Intravenous injection for chemotherapy-induced nausea and vomiting; Recalbon tablets to treat osteoporosis; Staybla tablets for the treatment of overactive bladder; Opalmon tablets for peripheral circulatory disorder; and Onon capsules for the treatment of bronchial asthma and allergic rhinitis. The company’s products also comprise Onon dry syrup for the treatment of bronchial asthma and allergic rhinitis; Kinedak tablets for the treatment of diabetic peripheral neuropathy; Foipan tablets for the treatment of chronic pancreatitis and postoperative reflux esophagitis; Elaspol injection for the treatment of acute lung injury associated with systemic inflammatory response syndrome; Onoact injection for the treatment of tachyarrhythmia; and ORENCIA injection for the treatment of rheumatoid arthritis. In addition, it is involved in developing drugs for various indications, such as melanoma, renal cell carcinoma, non-small cell lung cancer, bronchial asthma, allergic rhinitis, irritable bowel syndrome, glaucoma, ocular hypertension, B-cell lymphoma, underactive bladder, gastroesophageal reflux disease, Parkinson’s disease, portal hypertension, acute heart failure, head and neck carcinoma, glioblastoma, diffuse large b cell lymphoma, follicular lymphoma, chronic myeloid leukemia, and juvenile idiopathic arthritis, as well as esophageal, ovarian, and colon cancer. Ono Pharmaceutical Co., Ltd. has drug discovery strategic alliances with Array BioPharma Inc.; Locus Pharmaceuticals, Inc.; BioSeek LLC; Receptos Inc.; Xention Limited; BioFocus DPI Limited; Evotec AG; Scil Proteins GmbH; and Domain Therapeutics S.A. The company was founded in 1717 and is headquartered in Osaka, Japan.

2,858 Employees
Last Reported Date: 06/30/14
Founded in 1717

ono pharmaceutical co ltd (4528) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ono pharmaceutical co ltd (4528) Key Developments

Ono Pharmaceutical Co. Ltd. and Gilead Sciences Inc. Enters into Exclusive License Agreement for the Development and Commercialization of ONO-4059

Ono pharmaceutical co. ltd. and Gilead Sciences Inc. (GILD) entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONO's oral Bruton's tyrosine kinase or BTK inhibitor for the treatment of B-cell malignancies and other diseases. As per the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations (ASEAN) countries, where ONO retains development and commercialization rights. ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO has presented preliminary Phase 1 data showing clinical activity in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) at several scientific conferences. ONO and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gilead's portfolio.

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announces Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Ono Pharmaceutical Co.,Ltd. Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors. Opdivo, launched in Japan in September 2014 for the treatment of patients with unresectable melanoma, is being developed in multiple tumor types in more than 50 clinical trials worldwide. Mogamulizumab was launched in Japan in May 2012 for the treatment of relapsed or refractory CCR4-positive Adult T-cell Leukemia-Lymphoma (ATL), and granted the indication expansion in March 2014 for relapsed or refractory CCR4-positive Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Clinical trials with mogamulizumab in ATL, PTCL, and CTCL are ongoing in the U.S., European Union (EU) and other countries. Opdivo and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Opdivo binds to the checkpoint receptor PD-1 expressed on activated T-cells, blocking this pathway and enabling the immune system to attack tumors, while mogamulizumab can suppress some of the immune cells that shield the tumor from the immune system. Pre-clinical evidence for each therapy suggests the combination of Opdivo and mogamulizumab may lead to an enhanced anti-tumor immune response compared to either agent alone.

Ono Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for Six Months Ended Sept. 30, 2014; Provides Earnings Guidance for the Full Year Ending March 31, 2015

Ono Pharmaceutical Co., Ltd. announced consolidated earnings results for six months ended Sept. 30, 2014. For the period, the company reported revenue of ¥62,381 million, operating profit of ¥3,026 million, profit before tax of ¥4,697 million, profit attributable to owners of the parent company of ¥3,281 million or ¥30.95 per basic share net cash provided by operating activities of ¥4,143 million, purchases of property, plant and equipment of ¥4,996 million, purchases of intangible assets of ¥12,580 million compared to the revenue of ¥70,740 million, operating profit of ¥15,041 million, profit before tax of ¥16,649 million, profit attributable to owners of the parent company of ¥11,530 million or ¥108.75 per basic share net cash provided by operating activities of ¥16,165 million, purchases of property, plant and equipment of ¥2,523 million, purchases of intangible assets of ¥3,283 million for the same period a year ago. The company provided earnings guidance for the full year ending March 31, 2015. For the year, the company expects revenue of ¥129,400 million, operating profit of ¥13,100 million, profit before tax was of ¥15,700 million and profit attributable to owners of the company of ¥10,900 million or ¥102.82 per basic share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4528:JP ¥12,250.00 JPY +130.00

4528 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4528.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4528 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONO PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at